Live Breaking News & Updates on Vedotin Trials

Stay updated with breaking news from Vedotin trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SEAGEN INC. : Stock Market News and Information | SGEN| US81181C1045

- Long-term follow-up data for PADCEV® with KEYTRUDA® in advanced bladder cancer to be featured as oral presentation –

- Updated Phase 1 data on first-in-class integrin beta-6. | April 26, 2023 ....

United States , Disitamab Vedotin , Enfortumab Vedotin , Roger Dansey , Seagen Inc , Exchange Commission , European Union , Presentations Of Company , American Society Of Clinical Oncology , Clinical Oncology , Annual Meeting , Chief Medical Officer , Vedotin Trials , Pipeline Trials , Annual Report , Seagen Inc Stock Exchange , Press Release , Ntegrin Sgen Us81181c1045 ,